Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Canbridge Pharmaceuticals Inc (1228)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.37 -0.06    -12.94%
03:59:50 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  KYG1821D1097 
  • Volume: 116,000
  • Bid/Ask: 0.37 / 0.43
  • Day's Range: 0.37 - 0.45
Canbridge Pharmaceuticals 0.37 -0.06 -12.94%

Canbridge Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Canbridge Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

117

Equity Type

ORD

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Contact Information

Address Unit 18, 6th Floor Building 21
No. 388 Xinping Street Suzhou Industrial Park Suzhou,
China
Phone 86 10 8414 8018
Fax -

Top Executives

Name Age Since Title
Peng Kuan Chan 59 2021 Independent Non-Executive Director
Richard James Gregory 65 2020 Independent Non-Executive Director
James Qun Xue 53 2018 Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board
James Arthur Geraghty 68 2018 Independent Non-Executive Director
Kan Chen 40 2021 Non-Executive Director
Edward Hu 60 2022 Non-Executive Director
Mark A. Goldberg 69 - Member of Strategic Advisory Board
Anthony Amato - 2022 Member of Scientific Advisory Board
Sushrut Waikar - 2022 Member of Scientific Advisory Board
Lan Hu 54 2022 Independent Non-Executive Director
Guangping Gao - 2020 Member of Strategic Advisory Board
Robert Colvin - 2022 Member of Scientific Advisory Board
Richard Polisson - 2022 Member of Scientific Advisory Board
Jean Francis - 2022 Member of Scientific Advisory Board
Brian Weinshenker - 2022 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1228 Comments

Write your thoughts about Canbridge Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email